Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.
about
Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015Early Experience of Sofosbuvir based Combination Therapy in "Real-Life" Cohort with Chronic Hepatitis-C Infection.Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability?Hepatobiliary quiz 11 (2014)Most Patients of Hepatitis C Virus Infection in India Present Late for Interferon-Based Antiviral Treatment: An Epidemiological Study of 777 Patients from a North Indian Tertiary Care Center.NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in "real-life" cohort.Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India.Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?
P2860
Q30355190-A646A3A2-A391-450C-936D-94C570515E06Q30375305-5B31E806-62D2-499D-ADDF-0D0A073A46AAQ33666545-445FCA82-9C81-4105-8794-3E10515F593FQ33978118-8C7C16FC-FA2A-4D79-85BD-4560EFEEE8F7Q34825710-205C875E-2A1D-46DF-8CF9-2C0D770631DAQ35818327-E6A98716-65F1-4FD7-97AB-8535AD0FB6ADQ38699377-C3302EF5-49CC-4CE1-99FA-7CA85097AAB5Q39206084-98A24048-44B9-4C2E-BA81-C57397FD5ED6Q39394909-5428DE93-1405-4137-998B-C96B8E509FA6Q40143151-F0C2AB56-1A87-442A-B6CD-9DC42DFC0711Q40416893-3F803F27-A5C2-4725-AC7F-3883E8F5AAE8Q52597017-C068612D-DE38-439C-8446-A58E9B6387EB
P2860
Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Consensus Statement of HCV Tas ...... or Management of HCV in India.
@ast
Consensus Statement of HCV Tas ...... or Management of HCV in India.
@en
type
label
Consensus Statement of HCV Tas ...... or Management of HCV in India.
@ast
Consensus Statement of HCV Tas ...... or Management of HCV in India.
@en
prefLabel
Consensus Statement of HCV Tas ...... or Management of HCV in India.
@ast
Consensus Statement of HCV Tas ...... or Management of HCV in India.
@en
P2093
P2860
P1476
Consensus Statement of HCV Tas ...... or Management of HCV in India.
@en
P2093
Aabha Nagral
Abraham Koshy
Ajay Duseja
Ajay K Jain
Amarendra S Puri
Anil Arora
Ashish Kumar
Deepak Amarapurkar
Dharmesh Kapoor
P2860
P304
P356
10.1016/J.JCEH.2014.06.001
P577
2014-06-24T00:00:00Z